Harpoon Therapeutics Inc (NASDAQ:HARP)’s share price rose 6.2% during trading on Wednesday . The stock traded as high as $15.75 and last traded at $15.52, approximately 109,100 shares traded hands during mid-day trading. An increase of 181% from the average daily volume of 38,801 shares. The stock had previously closed at $14.61.
A number of equities analysts have recently weighed in on the company. Citigroup reiterated a “buy” rating and set a $23.00 target price on shares of Harpoon Therapeutics in a research note on Friday, May 24th. Zacks Investment Research upgraded Harpoon Therapeutics from a “hold” rating to a “buy” rating and set a $15.00 price target for the company in a research note on Friday, August 9th. Six analysts have rated the stock with a buy rating, Harpoon Therapeutics has a consensus rating of “Buy” and a consensus target price of $22.00.
The stock’s 50-day moving average price is $13.62 and its 200-day moving average price is $12.67. The company has a market cap of $367.17 million and a P/E ratio of -0.61. The company has a debt-to-equity ratio of 0.12, a current ratio of 9.47 and a quick ratio of 9.47.
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Northern Trust Corp grew its position in shares of Harpoon Therapeutics by 9.4% during the 2nd quarter. Northern Trust Corp now owns 35,745 shares of the company’s stock worth $465,000 after purchasing an additional 3,072 shares in the last quarter. Charles Schwab Investment Management Inc. raised its position in shares of Harpoon Therapeutics by 24.0% in the second quarter. Charles Schwab Investment Management Inc. now owns 37,399 shares of the company’s stock valued at $487,000 after buying an additional 7,232 shares in the last quarter. Wells Fargo & Company MN acquired a new stake in shares of Harpoon Therapeutics in the second quarter valued at approximately $94,000. EcoR1 Capital LLC boosted its stake in shares of Harpoon Therapeutics by 0.9% in the second quarter. EcoR1 Capital LLC now owns 1,348,423 shares of the company’s stock valued at $17,529,000 after buying an additional 12,000 shares during the period. Finally, Vanguard Group Inc. boosted its stake in shares of Harpoon Therapeutics by 183.3% in the second quarter. Vanguard Group Inc. now owns 234,377 shares of the company’s stock valued at $3,047,000 after buying an additional 151,644 shares during the period. 56.44% of the stock is owned by hedge funds and other institutional investors.
Harpoon Therapeutics Company Profile (NASDAQ:HARP)
Harpoon Therapeutics, Inc, a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company's lead TriTAC product candidate is HPN424 that is in Phase I clinical trial for the treatment of metastatic castration-resistant prostate cancer.
Read More: Sell-Side Analysts
Receive News & Ratings for Harpoon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harpoon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.